Four Cancer Treatments Available at CHIPSA – But NOT the Rest of the World

The world has come a long way in the last few decades in its ability to treat cancer. Yet many people still die from the disease, creating growing frustrations regarding the lack of treatment options. It seems as if the standard of care protocols have remained unchanged for 30 years: chemotherapy, radiation and surgery.  

Furthermore, any new “idea” for cancer treatment is almost immediately frowned upon.

But recently, the tide has begun to change. Studies show that harnessing the power of the immune system could also play a big role in treating cancer.

integrative oncology
Drs. James P. Allison & Tasuku Jongo,
Nobel Prize Winners 2018

In fact, immunotherapy won the Nobel Prize in medicine in both 2011 and 2018, and the FDA has done an impressive job over the last 10 years in approving therapies that drastically extend patient survival.


Unfortunately, the system is still very slow, and getting combination therapy can be difficult.

For over 40 years, the practice here at CHIPSA Hospital has been on the forefront of advanced integrative treatments and immunological therapies.

Chipsa Main Entrance
CHIPSA Hospital, Tijuana, Mexico

Several of our treatments have achieved long-term success on their own. In fact, a five-year melanoma study at CHIPSA, published in peer-reviewed medical journals, yielded a 600% increase in five-year survival for stage 4 melanoma.

Some of the patients at CHIPSA have their oncologists work with our doctors at CHIPSA to combine the best of conventional therapy with the treatments we do in Mexico.


Instead of waiting for a clinical trial, many patients come to CHIPSA to get treatments that aren’t available in the United States or the rest of the world. Many of these patients were told they had a terminal disease and had no hope.

This makes the regression of their cancer even more impressive.

Below is a list of four treatments that are available at CHIPSA, but not in the United States.

Coley’s CPG ™

Coley’s CPG therapy is CHIPSA’s custom-made proprietary blend of Coley’s toxins that has a focus on CPG. CPG is one of the danger signals in Coley’s toxins. Pfizer bought  “Coley’s Pharmaceutical” who owned a patent for CPG and ran some clinical trials. There are many studies going on right now with CPG and checkpoint inhibitors. The idea is to turn a tumor from cold to hot meaning a tumor that previously couldn’t be seen by the immune system is now recognized, or “hot.” 

The Coley’s CPG at CHIPSA is really just Coley’s toxins with the chemist picking specific strains of bacteria that has more CPG. Many scientists would say that Coley’s toxins is the best adjuvant out there. It has multiple danger signals, including CPG, and from 1891-1936 was reported to have a higher success rate treating most cancers than we do today. Dr. William Coley is noted in textbooks as the “Father of Immunotherapy”. His daughter, Helen Coley Nauts, founded the Cancer Research Institute in 1952.

Coley’s toxins was banned in the U.S. in 1962 as the medical community was convinced chemotherapy was going to be the answer. While they were well intended they missed the mark and ended up studying chemotherapy for solid tumors for many years.

Historically, the cancers that respond well to chemotherapy are Leukemia, Lymphoma and testicular Cancers – two blood cancers and a cancer of the testicals. Full cures can be found with these cancers. Solid tumor cancers on the other hand, at the stage 4 level, are generally not curable with chemotherapy. 

This is why the published monographs of Helen Coley Nauts are so impressive. They beat 5 year survival of many cancers even today. 

“This fortuitous combination of Gram-positive and Gram-negative bacteria possessed a wide array of immunostimulatory properties that allowed Dr. Coley to achieve excellent long-term cure rates that in some instances remain unrivaled by medical science in the 81 years since his death.”

Apatone+ ™

Apatone is a proprietary therapy that exhibits synergistic anti-tumor activity and preferentially kills tumor cells by autoschizis. Autoschizis uses a series of self-excisions to induce a type of cell death characterized by exaggerated membrane damage and progressive loss of organelle-free cytoplasm.

A number of studies show that Apatone works synergistically with chemotherapy. Some show a 600% increase in cell death when Apatone is combined with chemotherapy. 

There was a phase 1 FDA study with Apatone as a stand-alone treatment for prostate cancer. Phase 1 studies are in place to test safety but this study also showed the velocity of the PSA’s rising to slow tremendously. 

At CHIPSA, Apatone is used as both an IV infusion and oral pill form. Generally the doctors time the use on specific days with low dose chemotherapy. Their idea is that a patient might be able to use less chemo but get the same or bigger effect as a high dose because it’s being used with Apatone. 

To learn more about Apatone, visit the links below:

DC-Max ™

Multiple studies are going on in the United States and throughout the world focusing on Dendritic cell vaccines for patients. The first FDA-approved dendritic cell treatment was called Provenge, which led to a Nobel Prize. This treatment is now approved, but at the high cost of approximately $94,000 to the patient for just 3 doses. CHIPSA is able to offer dendritic cell treatments to patients for a fraction of the cost.

It is only available in the U.S. for prostate cancer. CHIPSA is able to treat multiple forms of cancer with dendritic cells. 

The approaches in trials throughout the world use stored antigens that are not from the patient. We believe the very best possible tumor antigen is from the patient’s own body. CHIPSA expands the dendritic cells and gives them back to the patients while using cytotoxic agents like low dose chemotherapy or Apatone.

This personalized version of this cellular product is unique to CHIPSA. Dendritic cells are used by patients who are currently undergoing conventional therapy or want CHIPSA’s full combination approach.

VG-5000 ™

VG-5000 builds upon the work of the acclaimed Russian immunologist Dr. Valentine Govallo. Dr. Govallo had over 40 years of experience in clinical immunology.

He is the author of 294 scientific papers and 19 scientific books. His vaccine was derived from full-term donated placentas which are normally thrown away after birth. He noticed that the immune system didn’t attack a placenta as it was being formed, and hypothesized that it would have the same defense mechanisms as a tumor.

In the 1970s, according to his book, he treated 35 patients with various solid tumor carcinomas (lung cancer, breast cancer, colorectal, melanoma) and reported a 65% 10-year survival rate. 

Later generations of the vaccine were made and used in different parts of the world and recently other companies have made similar vaccines and defended mechanisms of action. VG-5000 stands for what is the 5th generation and most scientifically studied version of his vaccine. 

Here is more information on Dr. Govallo and his treatments.

What’s Next For Cancer Treatment?

In our quest to find out what works, CHIPSA also wants to make it clear that although we strongly believe in our protocols, we are not aware of an all out cure for cancer.

We are committed to staying on the forefront of every possible answer for this disease. Cancer attacks the body from so many different angles, there is no easy answer for it.


immunotherapy and NF1-gliomas

While we can’t guarantee your result, what we can assure you is that we have more experience than any other clinic in North America when it comes to combining the most powerful natural therapies and cutting edge immunotherapies, in combination with other modern treatments for cancer.



If you or someone you love would like to see how CHIPSA might be able to support your healing journey, please click the button below us a call directly at 1-888-667-3640. We will schedule you a free 30 minute appointment to talk to one of our doctors and see what may be possible.